WuXi XDC Posts Record Backlog and First Commercial Revenue as Linker-Payload Business Outpaces Core Growth
Interim results call, August 25, 2026
WuXi XDC Cayman Inc. delivered a first half that management called "another outstanding" period, with revenue rising 37% year-over-year to RMB 3.7 billion on an actual exchange rate basis, or 41.5% on a constant-currency basis. But the more consequential disclosures came underneath the headline growth number: the company booked its first-ever commercial manufacturing backlog, signed a record 51 integrated CMC (iCMC) projects, and confirmed that its linker-payload franchise is now growing faster than the core XDC business. Together, these signal a company transitioning from a pure development-stage CDMO into one with visible, near-term commercial manufacturing revenue.
Commercial Backlog Inflection Point
The single most important data point in the release is the emergence of a commercial-stage backlog. CFO Michael Xi disclosed that total service backlog reached just under $2 billion, up 50.4% year-over-year, and that for the first time roughly $120 million of that figure came from commercial-stage contracts. Including newly disclosed milestone and royalty income of approximately $150 million, total backlog growth reaches 62% year-over-year. "This is the beginning," Xi said. "As you can see, this year we started to record backlog from commercial stage, and I think with more programs moving to a later stage, we should be able to see larger and larger numbers from commercial-stage backlog." Management is guiding to 4 to 6 BLA submissions in 2026, scaling to 12 to 15 by 2028, with a target of deriving 20% of revenue from commercial manufacturing by 2030.
Linker-Payload Business Becomes the New Growth Engine
CEO Jimmy Li disclosed that, starting in 2026, the linker-payload segment is growing faster than the consolidated XDC business — a notable shift in the growth mix. The company has now signed over 10 PPQ (process performance qualification) contracts specifically for linker-payload components and is expanding into newer payload classes including linker-oligo conjugates, LNPs, PROTACs and GalNAc, alongside its established WuXiTecan-2 hydrophilic linker platform. The Jiangyin site — an 80,000-square-meter commercial-scale facility — is being built specifically to support this shift, manufacturing not just highly potent linker payloads but also peptides and oligo components for antibody-oligo and antibody-peptide conjugates (AOCs and APCs). Li framed this as a structural bet: "Our innovation, our continued capability in terms of the peptides, oligos, as well as our aggressive expansion on the commercial capacity will ensure that the payload-linker business becomes a faster growth engine for XDC Group in the next few years."
Losing the Merck Commercial Award — and Why Management Says It Doesn't Matter
In a moment of unusual candor, CFO Xi directly addressed investor concerns over a closely watched ADC program widely understood to be Merck's. He confirmed that WuXi XDC remains the sole supplier for clinical supply but was passed over for the commercial award because "we haven't built our track record in end-stage yet." Rather than downplay the setback, Xi used it to reframe the investment thesis away from single-project risk: "Don't focus on just one project — we don't count on a single project. What you should focus on is the fact that we already signed 21 PPQ projects, one-third of those for first-line indications, and around nine are international projects. We already have two commercial projects on hand. It's just a matter of time." He also flagged a structural argument that deserves scrutiny: as more ADCs reach commercialization industry-wide, he expects a supply-demand gap to widen, benefiting capacity holders like WuXi XDC regardless of which specific contracts are won or lost.
Singapore Live, But Ramp Will Be Slow and Deliberate
The Singapore site — pitched for two years as critical to supply-chain resilience for multinational clients — has now transitioned from construction to operation, with GMP release of its mAb and BCM3 lines on August 17 and DP4 to follow within days. However, management was explicit that revenue contribution will lag facility readiness. Li explained that multinational clients require internal quality audits before placing commercial orders, and that Singapore's ramp will be structurally slower than a typical China site launch: "We don't have much pressure to try to ramp up as quickly as we typically do at the WuXi site. We wanted to start to build execution record... hopefully more significant backlogs will start to build up by early next year." Investors should treat Singapore as a 2027-and-beyond revenue story, not a near-term catalyst, despite its strategic value as a dual-sourcing option for clients wary of geographic concentration risk.
BioDlink Consolidation Muddies But Doesn't Break the Margin Story
The first-time consolidation of BioDlink (acquired late March, majority-owned via WuXi Bio structure) complicates period-over-period comparisons. On a consolidated basis, gross margin still expanded to 37% from 36.1% a year earlier, and adjusted net profit crossed RMB 1 billion for the first half for the first time, with margin holding at 27.8% — notable given that BioDlink is loss-making. Management attributed the margin resilience to a higher mix of high-value-added services and sustained high capacity utilization. On a standalone basis (excluding BioDlink), gross margin was stronger still, at 37.6%, up from 36%. Xi cautioned that second-half margins face headwinds from Singapore ramp-up costs and continued BioDlink losses, guiding to roughly flat full-year gross margin versus 2025, with any deviation unlikely to exceed a point in either direction.
Guidance Held, Not Raised — Capacity Is the Constraint
Despite the parent company, WuXi Biologics, raising its own full-year guidance, WuXi XDC management explicitly declined to follow suit. Xi was direct about why: "We already have a very high growth rate — I think that we will not further increase our guidance. Bear in mind, all of our capacities are actually running at a high utilization ratio." The company reiterated 35% constant-currency revenue growth on a standalone basis and roughly 30% on a consolidated basis for the full year, with Xi suggesting growth could reaccelerate once new production facilities — including BCM4 by year-end and DP5/DP6 in 2027 and 2028 — come online. This is a useful signal for investors: the binding constraint on WuXi XDC's growth right now is physical capacity, not demand.
Market Share and Competitive Position Versus Lonza
On competitive dynamics, Li estimated WuXi XDC's share of new iCMC signings at "40 plus/minus percent" of the addressable market, while declining to give a precise commercial-stage market share figure. More significant was his claim that, based on full-year 2025 results, WuXi XDC has reached rough revenue parity with Lonza, historically the ADC CDMO industry leader. Li was measured on new entrants Samsung Biologics and Lonza's own capacity expansions, arguing the competitive landscape "has not changed much over the past couple of years" and that WuXi's integrated discovery-to-commercial model remains differentiated. Separately, management disclosed that every M&A transaction involving an ADC/XDC-focused biotech in the first half of 2026 — roughly five to six deals — involved a WuXi XDC client, underscoring the platform's entrenchment with sponsors that ultimately get acquired by large pharma.
AI Entrants and Licensing Deals as an Emerging Funnel Source
Following its first licensing deal earlier in 2026 with Earendil Labs, an AI-powered protein therapeutics company, WuXi XDC disclosed a second licensing agreement with an unnamed European biotech, to be announced shortly. Li noted that technology companies are increasingly entering the biotherapeutics field via AI-designed molecules, and that WuXi XDC has already begun providing services to such entrants. Management was careful to note that milestone and royalty payments tied to these deals are not embedded in guidance given their unpredictable timing, framing any such income as "a bonus upside" rather than a base-case assumption — a reasonable disclosure practice that tempers what could otherwise become an overhyped narrative around licensing monetization.